Yamanouchi Wowtab licensing
This article was originally published in The Tan Sheet
Executive Summary
New OTC incorporating quick-dissolve technology could reach U.S. market as early as September under licensing deal with Intech Pharmaceuticals announced April 12. Intech obtains exclusive, worldwide rights (outside Japan) for development, marketing of quick-dissolve OTC, Rx products using the technology. Yamanouchi Pharma Technologies retains manufacturing rights and will receive royalties on product sales. Intech said it is in the process of finalizing its first agreement for an OTC product. Pfizer Consumer Healthcare's Benadryl Children's Allergy/Cold Fastmelt is the only OTC currently available in the U.S. featuring the Wowtab delivery form...